Liposomal chemotherapy combination

0 marketed 2 in Phase 3

This page covers all Liposomal chemotherapy combination drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting DNA (topoisomerase II for daunorubicin; DNA polymerase for cytarabine), DNA polymerase (cytarabine); Topoisomerase II (daunorubicin).

Targets

DNA (topoisomerase II for daunorubicin; DNA polymerase for cytarabine) · DNA polymerase (cytarabine); Topoisomerase II (daunorubicin)

Phase 3 pipeline (2)

Liposome-encapsulated Daunorubicin-Cytarabine · Fred Hutchinson Cancer Center · Oncology
A liposome-encapsulated combination of two chemotherapy drugs (daunorubicin and cytarabine) that delivers cytotoxic agents directly into leukemic cells to inhibit DNA synthesis and induce cell death.
Liposomal cytarabine-daunorubicin for injection · CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · Oncology
This liposomal formulation delivers cytarabine and daunorubicin directly into leukemic cells, where both drugs inhibit DNA synthesis and induce apoptosis.